BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics total assets
Total assets on the balance sheet at the end of each period.
BioXcel Therapeutics's total assets was $28.80M at Jun 30, 2026. For fiscal 2025 it was $44.92M, up 17.2% from the year before. The highest annual figure on record is $239.44M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.92M | +17.2% |
| FY2024 | Dec 31, 2024 | $38.34M | -48.0% |
| FY2023 | Dec 31, 2023 | $73.70M | -64.2% |
| FY2022 | Dec 31, 2022 | $205.85M | -14.0% |
| FY2021 | Dec 31, 2021 | $239.44M | +8.9% |
| FY2020 | Dec 31, 2020 | $219.94M | +504.4% |
| FY2019 | Dec 31, 2019 | $36.39M | -16.4% |
| FY2018 | Dec 31, 2018 | $43.55M | +3113.9% |
| FY2017 | Dec 31, 2017 | $1.36M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $28.80M | +11.7% |
| Q1 FY2026 | Mar 31, 2026 | $34.03M | -11.8% |
| Q4 FY2025 | Dec 31, 2025 | $44.92M | +17.2% |
| Q3 FY2025 | Sep 30, 2025 | $44.79M | -8.4% |
| Q2 FY2025 | Jun 30, 2025 | $25.79M | -60.6% |
| Q1 FY2025 | Mar 31, 2025 | $38.57M | -53.2% |
| Q4 FY2024 | Dec 31, 2024 | $38.34M | -48.0% |
| Q3 FY2024 | Sep 30, 2024 | $48.89M | -51.3% |
| Q2 FY2024 | Jun 30, 2024 | $65.44M | -53.3% |
| Q1 FY2024 | Mar 31, 2024 | $82.32M | -54.3% |
| Q4 FY2023 | Dec 31, 2023 | $73.70M | -64.2% |
| Q3 FY2023 | Sep 30, 2023 | $100.45M | -59.0% |
| Q2 FY2023 | Jun 30, 2023 | $140.10M | -43.6% |
| Q1 FY2023 | Mar 31, 2023 | $180.10M | -14.7% |
| Q4 FY2022 | Dec 31, 2022 | $205.85M | -14.0% |
| Q3 FY2022 | Sep 30, 2022 | $244.82M | -6.3% |
| Q2 FY2022 | Jun 30, 2022 | $248.24M | -11.7% |
| Q1 FY2022 | Mar 31, 2022 | $211.05M | +5.3% |
| Q4 FY2021 | Dec 31, 2021 | $239.44M | +8.9% |
| Q3 FY2021 | Sep 30, 2021 | $261.33M | +9.5% |
| Q2 FY2021 | Jun 30, 2021 | $281.11M | +298.9% |
| Q1 FY2021 | Mar 31, 2021 | $200.39M | +133.5% |
| Q4 FY2020 | Dec 31, 2020 | $219.94M | +504.4% |
| Q3 FY2020 | Sep 30, 2020 | $238.75M | +446.4% |
| Q2 FY2020 | Jun 30, 2020 | $70.46M | +105.6% |
| Q1 FY2020 | Mar 31, 2020 | $85.81M | +112.8% |
| Q4 FY2019 | Dec 31, 2019 | $36.39M | -16.4% |
| Q3 FY2019 | Sep 30, 2019 | $43.70M | -8.7% |
| Q2 FY2019 | Jun 30, 2019 | $34.28M | -33.1% |
| Q1 FY2019 | Mar 31, 2019 | $40.33M | -28.4% |
| Q4 FY2018 | Dec 31, 2018 | $43.55M | +3113.9% |
| Q3 FY2018 | Sep 30, 2018 | $47.87M | – |
| Q2 FY2018 | Jun 30, 2018 | $51.21M | – |
| Q1 FY2018 | Mar 31, 2018 | $56.32M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.36M | – |
See a number that looks wrong?